News & Events

In this live recording from DCAT, our CEO Franco Negron speaks with Raman Sehgal, host of the "Molecule to Market" podcast, and Alessandro Maselli, President and CEO of Catalent, about the transformation of CDMOs from enablers to systemically important partners. Hosted by Morgan Stanley, the panel addressed the latest issues in global drug manufacturing and development, including how the pace of scientific innovation is changing the market and the value of strategic use of AI for both customers and employees.

In this Health Tech World podcast, Lupe Rojas and Sean Knight of Simtra’s business development team explore the evolution of the injectables market and manufacturing demand for sterile injectable therapies, from ADCs in oncology to GLP‑1 weight‑loss drugs.The conversation takes a deeper look at the factors influencing how CDMOs are structuring their supply chains to meet the global demand.

 

Simtra BioPharma Solutions CEO Franco Negron sat down with BioPharma International during DCAT to talk about the key drivers behind our growth strategy and how we stay ahead of evolving market trends. Discover the rationale behind our recent investments — and how they position Simtra to better support our clients and their patients.

In this new article for Contract Pharma, Simtra BioPharma Solutions CEO Franco Negron discusses how we combine our legacy of 65+ years of experience in manufacturing sterile injectables with a culture of continuous improvement and workforce development. When it comes to investing in new technology like AI, he says, “Our goal is not to replace people but to improve outcomes, strengthen customer service and develop our workforce.” Read more about the market forces — and the strategy — driving our growth.

Writing in Biopharm International, Mike Schaefers, Chief Commercial Officer at Simtra BioPharma Solutions outlines why the future of drug development lies in a continuum of CDMO expertise—where strategic alliances replace fragmentation, compress timelines, reduce cost, and unlock faster paths from innovation to patient impact.

Simtra BioPharma Solutions is executing a bold, dual-continent expansion strategy to meet growing global demand for complex, high-value therapies.  

In this bylined article in PHARMAnetwork magazine, CEO Franco Negron outlines Simtra BioPharma Solutions’ global growth strategy and how our purpose-driven investments are shaping the future of sterile injectable manufacturing. With expanded capabilities in the United States and Germany, we’re building a resilient network to bring vital injectable products to our customers’ patients with speed, quality, and care.

In an article for Pharmaceutical Executive, Lidia Serina, Ph.D., head of development services at Simtra BioPharma Solutions, details how the right CDMO partner can help an emerging biotechnology company meet the challenges of launching a new drug in today’s competitive global environment and achieve sustainable commercial success.

Simtra BioPharma Solutions announces the purchase from Cook Group of a 65-acre property with more than 300,000 square feet of available space for expansion under-roof near its existing manufacturing facility in Bloomington, Indiana.